International Journal of Cardiology
Volume 150, Issue 1 , Pages 39-44 , 1 July 2011

Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease

  • Marie Lordkipanidzé

      Affiliations

    • Faculty of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • ,
  • Chantal Pharand

      Affiliations

    • Faculty of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • ,
  • Erick Schampaert

      Affiliations

    • Faculty of Medicine, Université de Montréal, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Cardiology Division, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • ,
  • Donald A. Palisaitis

      Affiliations

    • Faculty of Medicine, Université de Montréal, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Cardiology Division, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • ,
  • Jean G. Diodati

      Affiliations

    • Faculty of Medicine, Université de Montréal, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Cardiology Division, Hôpital du Sacré-Cœur de Montréal, Montréal, Canada
    • Corresponding Author InformationCorresponding author. Research Center, Hôpital du Sacré-Coeur de Montréal, 5400, boul. Gouin Ouest, Montréal, Québec, Canada H4J 1C5. Tel.: +1 514 338 2200; fax: +1 514 338 2694.

Received 13 November 2009 ,Revised 12 January 2010 ,Accepted 13 February 2010.

References 

  1. Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  2. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218
  3. Bracey AW, Grigore AM, Nussmeier NA. Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures. Am J Cardiol. 2006;98:25N–32N
  4. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics. 2004;3:133–144
  5. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122:379–391
  6. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost. 2009;7:241–246
  7. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res. 2006;98:593–595
  8. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68:11B–15B
  9. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489–e493
  10. Mani H, Luxembourg B, Klaffling C, Erbe M, Lindhoff-Last E. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol. 2005;58:747–750
  11. Riondino S, Trifiro E, Principessa L, Mascioletti S, Di Renzo L, Gaudio C, et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb Res. 2008;122:359–365
  12. Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost. 2006;95:476–482
  13. Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2008;68:185–191
  14. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46:1258–1263
  15. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153:175–181
  16. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–1708
  17. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980–1987
  18. Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol Ther. 2006;112:733–743
  19. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. PNAS. 2002;99:7634–7639
  20. Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets. 2006;17:163–169
  21. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542–547
  22. Guthikonda S, Lev EI, Patel R, Delao T, Bergeron AL, Dong JF, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007;5:490–496
  23. Lordkipanidzé M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol. 2009;
  24. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:743–749
  25. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007;5:82–90
  26. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006;95:652–658
  27. Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol. 2008;28:s17–s24
  28. Muir AR, Patterson C, McMullin MF, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95:1225–1229
  29. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593–1599
  30. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(10)00092-6

doi: 10.1016/j.ijcard.2010.02.025

International Journal of Cardiology
Volume 150, Issue 1 , Pages 39-44 , 1 July 2011

Article Tools

* Image Usage & Resolution